Update on the management of inflammatory breast cancer

Oncologist

Volumn 8, Issue 2, 2003, Pages 141-148

  Cristofanilli, Massimo ^a   Buzdar, Aman U ^a   Hortobágyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Inflammatory breast cancer; Targeted therapies

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CADHERIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN MDM2; PROTEIN P53; TAXANE DERIVATIVE; VINBLASTINE; VINCRISTINE;

BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; DRUG EFFICACY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; ONCOGENE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CLINICAL TRIALS; DISEASE MANAGEMENT; FEMALE; HUMANS; INCIDENCE; INFLAMMATION; NEOPLASM STAGING; UNITED STATES; WOMEN'S HEALTH;

EID: 0037255004     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-2-141     Document Type: Review

References (61)

1. Levine PH, Steinhorn SC, Ries LG et al. Inflammatory breast cancer. The experience of the Surveillance, Epidemiology, and End Results (SEER) program. J Natl Cancer Inst 1985;74:291-297.
2. Chang S, Parker SL, Pham T et al. Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, 1975-1992. Cancer 1998;82:2366-2372.
3. Bell C. A System of Operative Surgery, Volume 2. Hartford, CT: Hale and Homser, 1814:136.
4. Klotz H. Ueber Mastitis Carcinomatosa Gravidarum et Lactantium. Halle, Germany: Lipke, 1869:30.
5. Leich A. Peau d'orange in acute mammary carcinoma. Its causes and diagnostic value. Lancet 1909;1:861-863.
6. Schumann E. A study of carcinoma mastitoides. Ann Surg 1911;54:69-77.
7. Lee B, Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg Gynecol Obstet 1924;39:580-595.
8. Haagensen C. Diseases of the Breast, Second Edition. Philadelphia: Saunders, 1971:576-584.
9. Taylor G, Meltzer A. Inflammatory carcinoma of the breast. Am J Cancer 1938;33:33-49.
10. Droulias CA, Sewell CW, Mcsweeney MB et al. Inflammatory carcinoma of the breast: a correlation of clinical, radiologic and pathogic findings. Ann Surg 1976;184:217-222.
11. Denoix P. The Institut's contribution to factors guiding the choice of treatment. Phase I development. In: Denoix P, ed. Treatment of Malignant Breast Tumors, Recent Results in Cancer Research. Number 31. Berlin: Springer-Verlag, 1970:3-11.
12. Piera JM, Alonso MC, Ojeda MB et al. Locally advanced breast cancer with inflammatory component: a clinical entity with a poor prognosis. Radiother Oncol 1986;7:199-204.
13. Low JA, Berman AW, Steinberg SM et al. Long-term follow-up for inflammatory (IBC) and non-inflammatory (NIBC) stage III breast cancer patients treated with combination chemotherapy. Proc Am Soc Clin Oncol 2002;21:63a.
14. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014-1024.
15. Wang C, Griscom N. Inflammatory carcinoma of the breast: results following orthovoltage and supervoltage radiation therapy. Clin Radiol 1964;15:168-174.
16. Bruckman JE, Harris JR, Levene MB et al. Results of treating stage III carcinoma of the breast by primary radiation therapy. Cancer 1979;43:985-993.
17. Perez CA, Fields JN. Role of radiation therapy for locally advanced and inflammatory carcinoma of the breast. Oncology (Huntingt) 1987;1:81-94.
18. Barker JL, Montague ED, Peters LJ. Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy. Cancer 1980;45:625-629.
19. Koh EH, Buzdar AU, Ames FC et al. Inflammatory carcinoma of the breast: results of a combined-modality approach - M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol 1990;27:94-100.
20. Singletary SE, Ames FC, Buzdar AU. Management of inflammatory breast cancer. World J Surg 1994;18:87-92.
21. Buzdar AU, Singletary SE, Booser DJ et al. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin North Am 1995;4:715-734.
22. Ueno NT, Buzdar AU, Singletary SE et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321-329.
23. Cristofanilli M, Buzdar AU, Sneige N et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 2001;92:1775-1782.
24. Cristofanilli M, Fratarcangeli T, Esteva F et al. Weekly high-dose paclitaxel (HD-P) has significant antitumor activity in inflammatory breast cancer (IBC). Proceedings of the ECCO 11. Eur J Cancer 2001;37:S173.
25. Cristofanilli M, Kau SW, Buzdar AU et al. Paclitaxel significantly improves the prognosis in ER-negative inflammatory C C breast cancer (IBC): The M. D. Anderson Cancer Center Experience (1974-2000). Breast Cancer Res Treat 2002;76(suppl 1):S158a.
26. Guerin M, Gabillot M, Mathieu MC et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer 1989;43:201-208.
27. Aziz SA, Pervez S, Khan S et al. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J 2001;7:398-404.
28. Pro B, Cristofanilli M, Buzdar AU et al. The evaluation of p53, HER-2/neu, and serial MDR protein expression as possible markers of chemoresistance and their use as prognostic markers in inflammatory breast cancer. Proc Am Soc Clin Oncol 1998;17:553a.
29. Tagliabue E, Pilotti S, Gianni AM et al. Target molecules for immunotherapy of inflammatory breast carcinomas. Eur J Cancer 1998;34:1982-1983.
30. Kobayashi H, Shirakawa K, Kawamoto S et al. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(IB4M-Gd)(256). Cancer Res 2002;62:860-866.
31. Hurley J, Doliny P, Silva O et al. Neoadjuvant herceptin/Taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol 2002;21:50a.
32. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 2000;910:121-137; discussion 137-139.
33. Moll UM, LaQuaglia M, Benard J et al. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 1995;92:4407-4411.
34. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002;27:462-467.
35. An WG, Chuman Y, Fojo T et al. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. Exp Cell Res 1998;244:54-60.
36. Zhang Y, Xiong Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 1999;3:579-591.
37. Salh B, Marotta A, Wagey R et al. Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. Int J Cancer 2002;98:148-154.
38. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001;14:672-676.
39. Bose S, Crane A, Hibshoosh H et al. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 2002;33:405-409.
40. Bykov VJ, Issaeva N, Shilov A et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8:282-288.
41. Roth JA, Grammer SF, Swisher SG et al. P53 gene replacement for cancer - interactions with DNA damaging agents. Acta Oncol 2001;40:739-744.
42. Alpaugh ML, Tomlinson JS, Shao ZM et al. A novel human xenograft model of inflammatory breast cancer. Cancer Res 1999;59:5079-5084.
43. Shirakawa K, Tsuda H, Heike Y et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001;61:445-451.
44. Shirakawa K, Wakasugi H, Heike Y et al. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 2002;99:821-828.
45. Shirakawa K, Kobayashi H, Heike Y et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res 2002;62:560-566.
46. Shirakawa K, Shibuya M, Heike Y et al. Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. Int J Cancer 2002;99:344-351.
47. Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 2001;3:289-293.
48. Wheelock MJ, Soler AP, Knudsen KA. Cadherin junctions in mammary tumors. J Mammary Gland Biol Neoplasia 2001;6:275-285.
49. Parker C, Rampaul RS, Pinder SE et al. E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer 2001;85:1958-1963.
50. Kleer CG, van Golen KL, Braun T et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 2001;14:458-464.
51. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 2001;61:5231-5241.
52. Alpaugh ML, Tomlinson JS, Ye Y et al. Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol 2002;161:619-628.
53. van Golen KL, Wu ZF, Qiao XT et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000;60:5832-5838.
54. Kleer CG, Zhang Y, Pan Q et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 2002;21:3172-3180.
55. van Golen KL, Wu ZF, Qiao XT et al. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000;2:418-425.
56. Van Golen KL, Bao LW, Pan Q et al. Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis 2002;19:301-311.
57. End DW, Smets G, Todd AV et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61:131-137.
58. van Golen KL, Bao L, DiVito MM et al. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther 2002;1:575-583.
59. Fleming RY, Asmar L, Buzdar AU et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol 1997;4:452-461.
60. Green MC, Buzdar AU, Smith T et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC - Final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002;21:35a.
61. Huang E, McNeese MD, Strom EA et al. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys 2002;53:1225-1233.